Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.
That’s gene editing. On paper, it is merely the rearrangement of letters. However, the road to editing genes in hopes of a therapeutic benefit is difficult to travel. Additionally, researchers want ...
SHANGHAI, May 15, 2025 /PRNewswire/ -- Immunofoco, a company dedicated to advancing cell therapies for solid tumors, announced that its independently developed, innovative lentiviral vector-based In ...
MUNICH & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Through this license agreement, SIRION Biotech GmbH (“SIRION”) granted Cellectis non-exclusive right under its proprietary lentiviral transduction enhancer ...
MARTINSRIED, Germany--(BUSINESS WIRE)--SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products. CAR-T cell ...
Poster talk will present safety and efficacy data for ENaBL-T, a lentiviral vector for in vivo engineering of BCMA CAR T cells, which supported the first in vivo BCMA CAR-T cell therapy clinical trial ...
15d
Made Scientific and Syenex Forge Technology Partnership to Transform T Cell Therapy Manufacturing
Made Scientific, a leading cell therapy contract development and manufacturing organization (CDMO) and Syenex, a synthetic biology company specializing in best-in-class targeted delivery technologies, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback